Institutional accumulation regime. Strong business quality combined with supportive market trend. Valuations remain balanced and supported by current metrics.
SENTINEL REVIEW
3B Blackbio Dx Limited (3BBLACKBIO)•Updated yesterday
- ✗Risk score deteriorated (QoQ change: +5 pts)
- ✓Profitability margins pressure eased
- ✗Growth expectations are demanding
- ✓Market structure is neutral/stabilizing
- ✗Institutional flow regime is Strong Distribution (-2.46σ)
- ✗Share price is down -20.3% this quarter (from ₹1,710.4 on 30 Sept to ₹1,363)
- 🔴Investigate Operating Leverage Stress and balance sheet impact
- 🟠Track earnings quality and working capital trends in next filing
- 🟢Maintain routine quarterly surveillance; no governance escalation required
- 10.0 ptsGrowth Sustainability
- 9.9 ptsBalance Sheet Stress
Divergence Radar
Structural Matrix
Risk vs Price TimelineVisualizing the historical relationship between the structural risk score and stock price movement over time.
| Duration | Perf. | Sector Avg | Divergence |
|---|---|---|---|
| 1 Week | +3.34% | -1.46% | +4.81% |
| 1 Month | -14% | -6.69% | -7.3% |
| 6 Months | +13.37% | +6.82% | +6.54% |
| 1 Year | +3.22% | +8.93% | -5.71% |
| 2 Year | -1.61% | +47.64% | -49.25% |
| 3 Year | +73.79% | +125.5% | -51.7% |
Business Analysis Methodology
Business analysis focuses on structural risk inside the company. Flagium monitors earnings quality, balance sheet strength, liquidity, governance, competitive position, and growth sustainability to identify areas where risk may be increasing or decreasing before it becomes obvious in reported results.
Financial profile remains stable for now. Weakness is detected in growth sustainability. This suggests a building risk profile. Risk is increasing at a faster pace.
Risk Score Composition
Investment Risk Thesis
Current risk score has risen from 0 → 20 over 12 quarters.
- Operating profit margins
- Inventory turnover
Risk Drivers (Active Warnings)
Primary Driver & Insights
Asset turnover is slowing down due to inventory accumulation. This indicates potential channel stuffing or weaker demand in core product segments.
Active Risk Objects (3)Free Preview (2 of 3)
3BBLACKBIO: Inventory growth outpaced Revenue growth by +52.1 pp (Inventory holding ratio increased +35.2%).
Slight build-up in inventory detected. Monitor for slowing sales momentum.
Expenses are consistently growing faster than revenues, creating operational pressure.
Margins are in freefall. Operating costs are growing significantly faster than revenue.
Unlock All 3 Forensic Signals (1 Additional Warnings Gated)
Free accounts preview the top 2 highest-impact warning signals. Upgrade to Flagium Pro to inspect all 3 active forensic detectors, multi-quarter duration streaks, and financial stress metrics for 3B Blackbio Dx Limited.
Statutory Note: Forensic signals are algorithmic quantitative observations derived from publicly filed XBRL disclosures and do not constitute allegations of legal misconduct or investment recommendations.
Unlock Interactive Signal Evidence Dossier
Access complete multi-quarter financial evidence, 5-KPI snapshot strips, diagnostic hypotheses, and 1-page forensic PDF dossiers for 3B Blackbio Dx Limited.
Structural Risk Attribution
Deterministic quarter-on-quarter causal decomposition grounded in statutory exchange filings.
Structural History · Last 12 QuartersHistorical Trajectory (12Q)
Risk deteriorated moderately (+5.0 pts), driven by Universal Inventory Divergence (+1.2 pts) and Operating Leverage Stress (+1.2 pts).
Business Resilience & Benchmark Context
Overall: STRONGPEER COMPARISON MATRIX
Ranked surveillance & credit risk comparison against sector peers
Stable
Stable
Stable
Watch
Watch
Watch
* Peer comparison is based on risk signals, not valuation or returns.
Unlock 5-Year Forensic Divergence Cockpit
Access multi-year visual divergence charts (EBITDA vs CFO Cash Gap, Receivables Decoupling Spread, and Debt vs FCF Burn) for 3B Blackbio Dx Limited.
FINANCIAL STATEMENTS
Working Capital & Forensic Monitor
Operating Cycle Disclosures·10 Fiscal Years
Working Capital Schedule (INR Cr)
| Metric / Ratio | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Trade Receivables(₹ Cr) | — | — | — | — | — | — | — | — | — | — |
Inventories(₹ Cr) | 18 | 9 | 8 | 8 | 7 | 5 | 4 | 5 | 4 | 4 |
Trade Payables(₹ Cr) | 7 | 2 | 4 | 3 | 4 | 3 | 3 | 4 | 3 | 4 |
Net Working Capital(₹ Cr) | 11 | 7 | 4 | 5 | 3 | 2 | 1 | 1 | 1 | 0 |
Working Capital / Sales(%) | 7.8% | 7.3% | 5.5% | 7.5% | 4.3% | 0.9% | 2.1% | 4.7% | 2.3% | -1.8% |
Cash Conversion & Operating Cycle (Days)
| Metric / Ratio | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Cash Conversion Cycle (CCC)(days) | — | — | — | — | — | — | — | — | — | — |
Debtor Days (DSO)(days) | — | — | — | — | — | — | — | — | — | — |
Inventory Days (DIO)(days) | 46d | 34d | 39d | 47d | 32d | 8d | 50d | 79d | 63d | 91d |
Creditor Days (DPO)(days) | 18d | 7d | 19d | 20d | 16d | 5d | 43d | 62d | 55d | 98d |
Forensic Accounting Monitor & Divergences
| Metric / Ratio | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Receivable Growth vs Sales (Δ)(%) | — | — | — | — | — | — | — | — | — | — |
Inventory Growth vs Sales (Δ)(%) | +52.1% | -17.2% | -19.4% | +37.7% | +104.3% | -657.8% | -46.1% | +25.0% | -43.8% | — |
Asset Growth vs Sales (Δ)(%) | -20.2% | -10.4% | -3.5% | +34.9% | +63.3% | -351.6% | -1.1% | +20.0% | -28.4% | — |
Earnings-to-Cash Divergence (PAT - CFO)(₹ Cr) | 8 | 5 | 5 | 6 | -5 | 16 | 1 | 1 | 1 | 0 |
Accrual Ratio (Accruals / Avg Assets)(%) | 2.4% | 1.8% | 2.2% | 3.0% | -2.6% | 13.4% | 2.5% | 3.0% | 3.6% | 0.0% |
Operating Cash Realisation (CFO / EBITDA)(%) | 91.2% | 86.0% | 81.8% | 69.0% | 100.0% | 65.3% | 77.8% | 57.1% | 40.0% | 33.3% |
Capitalisation Intensity (CWIP / Assets)(%) | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Concall & Management Takeaways
No investor earnings call transcripts transcribed for this scrip.
Earnings call intelligence is automatically populated when companies conduct quarterly earnings calls with institutional investors and publish transcripts.
Business quality remains strong.
Current forensic pressure is elevated and stable.
Key risks remain concentrated in growth sustainability and operating leverage.
The risk profile is Early Signals and currently deteriorating. Recent structural triggers in growth sustainability suggest a building pressure on the underlying framework. Material forensic traces are visible in core structural metrics, indicating a progressive erosion of structural stability. Strategic vigilance is advised as structural decay is accelerating.
Market Expectation Engine
Investor Translation • What the market price is expecting
Expectation EngineAt the current price of ₹1,363, the market expects this company to grow its net profits by 26.1% every year for the next 5 years. If you think the company will grow faster than 26.1%, current market prices reflect a discount relative to that growth assumption.
Sentinel Takeaway:The market expects future growth in line with the company's historical delivery. Current market expectations appear balanced relative to the business's track record, representing standard expectation risk.
Using the Discounted Cash Flow (DCF) model, the market is pricing 3BBLACKBIO for 26.1% long-term growth versus 20.0% historical delivery. Current expectations appear demanding, and historical fundamentals provide strong support.
Business Delivery Capacity
Performance quality vs historical benchmarksHistorical business performance currently provides moderate support for the market's implied growth assumptions. Improvement in revenue growth and operating efficiency would strengthen expectation support.
WHY IS EXPECTATION RISK ELEVATED?
Valuation Context
WHAT MUST HAPPEN FOR CURRENT PRICE TO BE CORRECT?
| Assumption Metric | Required (To justify current price) | Historical Delivery (Average) | Fulfillment Assessment |
|---|---|---|---|
| Revenue Growth (CAGR) | 26.1% | 20.0% | Demanding |
| Operating Margin (EBIT) | 34.9% | 45.6% | Achievable |
| Free Cash Flow Conversion | 50.5% | 70.0% | Achievable |
*Required metrics indicate the operating efficiency and revenue expansion parameters that must be sustained long-term to justify the current stock price.
The current valuation assumes business performance broadly in line with the company's historical record. Historical operating performance currently provides partial evidence that these expectations are sustainable. Continued stronger profitability would be required to justify current pricing.
Market Structure Methodology
Flagium separates Business Risk from Market Structure. Business analysis explains what is happening inside the company. Market Structure measures how investors are behaving through price trends, momentum, participation, and institutional activity. Divergences between the two often reveal important transitions before they become obvious.
The stock remains in a confirmed Stage 1 accumulation phase. Institutional participation has also improved, reinforcing the an early-stage base trend as momentum is stabilizing. Current price action has not yet confirmed a breakout into an advancing trend.
What Is Driving Market Structure?
Market structure remains stable, but heavy distribution flows indicate institutional pressure.
Market Cycle Stage Analysis
Stan Weinstein 4-Stage CycleMomentum & Institutional Flow
Methodology & Regulatory Disclaimer
Flagium AI is an automated financial data analytics and research platform providing quantitative risk, forensic, and valuation analytics for informational and educational purposes only. Flagium AI is not registered with SEBI as a Research Analyst or Investment Adviser under SEBI regulations. These analytics do not constitute financial planning, investment advice, or recommendations to buy, sell, or hold any security.
Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered Investment Adviser before acting on any data presented.
📬 Flagium Risk Brief — Track forensic risks on 3BBLACKBIO & 3 market anomalies weekly
See a sample issue →